Kornimate/medical-research-clean huggingface dataset:
effects on shoulder pain of simulated hyper-gravity during rehabilitation exercises

Conditions: Shoulder Pain

Summary: determine if adding "extra-gravity" (sustained increase in vertical loading) during standard rehabilitation exercises has a beneficial effect on pain reduction in subjects suffering from shoulder pain of different origin.

standard rehabilitation protocols will be used with every subject, depending on the cause of their shoulder pain. the treating clinician will determine the appropriate therapy protocol for each subject. during the treatment sessions, subjects will wear a very comfortable waist belt attached with rubber band to anchor points on the ground (the rubber bands will be tighten to simulate the extra-gravity). upon enrollment, the treating clinician will randomly assign the subject to one of four groups depending on the type of loading and exercise typology. the hyper-gravity will be simulated as an additional 50% of subject's body weight. the frequency and duration of each therapy session will be determined by the treating clinician (usually 45 minutes of therapy twice a week for 4 weeks). before, after and 24h post therapy session, the subject will grade the pain level using a numeric pain scale (0 no pain; 10 unbearable pain requiring pain medication). as part of the rehabilitation therapy procedure, subjects will undergo shoulder range of motion evaluations (done by a trained clinician in approximately 3 minutes) and computer dynamic posturography (cdp) testing on a 4" tall foam cushion with eyes closed (psec test - less than 1 minute of testing) before and after each therapy session. subjects will complete the dash and tossa questionnaires (the total amount of time required to complete these assessment is \~20 minutes), and will be tested using the modified clinical testing of sensory integration in balance (mctsib) protocol (the subjects will be required to stand on a hard or compliant surface (a 4" tall foam cushion of known mechanical properties) in a comfortable posture, feet shoulder width, with eyes open or closed, head straight and arms to the side and free to move, gazing forward, and breathing normally, less than 2 minutes testing time) at the time of enrollment and at the end of the 4 week therapy program. subjects will be asked to come back for two more evaluations (questionnaires, range of motion assessment, and cdp testing) one month and three months after the end of the 4 week therapy program to identify possible long term effects of the "hyper-gravity/accentuated vertical loading" therapy.

Eligibility criteria:
inclusion criteria: * diagnosis of shoulder pain (potentially including rotator cuff pathology, impingement, bursitis, slap tear) exclusion criteria: * adhesive capsulitis, fracture, dislocation, inflammatory arthritis, cancer, ligament disruption

Keywords: balance, postural postural equilibrium pain scale range of motion
evaluation of the safety and effectiveness of allevyn gentle border

Conditions: Wound

Summary: the clinical study will evaluate the safety and effectiveness of the allevyn gentle border. the study is a post-market clinical follow-up to assess clinical performance and safety of allevyn gentle border with new wound contact layer to support performance claims.


Eligibility criteria:
inclusion criteria: 1. signed written informed consent. 2. 18 years of age or older. 3. willing and able to make all required study visits. 4. able to follow instructions and deemed capable of completing the cwis questionnaire, patient assessment scale and pain scale. 5. presence of a moderately to highly exuding wound of at least 3cm2 in size. 6. presence of a chronic wound of at least 6 weeks duration at the point of enrollment; full-thickness, partial thickness or shallow granulating wounds. chronic wounds include: * pressure ulcers or * leg ulcers or * diabetic foot ulcers or presence of an acute wound at the point of enrollment; full thickness, partial thickness or shallow granulating wounds acute wounds include: * dehisced surgical or * traumatic wounds 7. the patient has a wound size which can be treated with the available sizes and shapes of allevyn gentle border. cutting of the dressing is allowed, if needed. allevyn gentle border can be cut and an aseptic technique should be used with cutting the dressing. ensure any exposed foam areas are covered with an appropriate film dressing taking care not to cover the entire dressing. exclusion criteria: 1. subjects with confirmed or suspected clinically infected reference wound. 2. reference wound undergoing treatment with compression therapy. 3. contraindications or hypersensitivity to the use of the allevyn gentle border. 4. participation in the treatment period of another clinical trial within 30 days of visit 1 or planned participation overlapping with this study. 5. subjects with skin features (e.g. tattoos, skin color, pre-existing scarring) which, in the opinion of the investigator, could interfere with the study assessments. 6. subjects who have participated previously in this clinical trial. 7. subjects with a history of poor compliance with medical treatment. 8. subjects with a medical or physical condition that, in the opinion of the investigator, would preclude safe subject participation in the study

Keywords: chronic and acute wounds full-thickness partial thickness shadow granulating exuding wounds including pressure ulcers leg ulcers diabetic foot ulcers dehisced surgical wounds
the effect of radiofrequency-treatment on patients with facet-joint pain in cervical- and lumbar-columna

Conditions: Neck Pain; Low Back Pain

Summary: there is conflicting evidence on whether radio-frequency neurotomy of the medial branch has a significant effect on pain in patients with chronic unilateral facet joint neck and back pain. we will evaluate radiofrequency treatment on medial-branch of the ramus dorsalis as an effective pain treatment for patients with chronic pain originated from facet-joints in cervical and lumbar columna.


Eligibility criteria:
inclusion criteria: * one-sided neck and low back chronic pain * pain durability of at least 1 year exclusion criteria: * other somatic or psychiatric disorders * pregnancy * stated co-morbidity * anaesthetics intolerance * no effect of diagnostic blockades (one or two)

Keywords: radiofrequency
holter versus skiin garments

Conditions: Cardiac Arrhythmia

Summary: the goal of this observational study is to compare the electrocardiogram recording from holter monitor with textile sensors (in the form of clothing) in patients diagnosed with arrhythmia. the study aims to answer the following questions: * can the textile sensors provide continuous monitoring and detect arrhythmias? * do patients prefer to wear textile sensors instead of the holter? participants that need holter monitoring as part of their standard care will be invited to participate in the study. they will simultaneously wear both, the holter monitor and the textile sensors for the time prescribed by their physician. participants will also be asked to answer a questionnaire in the initial assessment and at the end of the study.


Eligibility criteria:
inclusion criteria: * being addressed to the pace cardiology clinic to perform an ecg due to a diagnosed or suspected cardiovascular disease. * age above 18 * understand and speak english enough to consent and answer the study questionnaire. * a medical need for holter monitoring, and having a personal smartphone (ios or android), compatible with the skiin app (application used to monitor the patient using the wearable device) exclusion criteria: * pregnancy * implanted defibrillator or pacemaker * absence of garment fitting the participant's body * open wound or dressing (e.g. band-aid) on a body part that needs to be in contact with the skiin electrodes * severe frailty such that donning or doffing the garment may cause a danger of fall. * sensitive skin

Keywords: ecg wearable holter
nutritional therapy in patients with post-extubation dysphagia

Conditions: Dysphagia

Summary: the aim of this study is to evaluate the impact of the prescription of two doses of protein on the amount in kilograms of muscle mass and on the clinical evolution (time until safe swallowing, time until removal of the feeding stoma, number of hospital readmissions, feeding stoma infections, incidence of pneumonia, functionality, number of falls, fractures and mortality) at 6 months after hospital discharge in patients with enteral nutrition due to post-extubation dysphagia.


Eligibility criteria:
inclusion criteria: * patients who required invasive mechanical ventilation during their hospital stay with a diagnosis of post-extubation dysphagia diagnosed by fibroendoscopy evaluation of swallowing (fees). * patients who discharged with a feeding tube. * patients with signed informed consent. exclusion criteria: * patients with pre-existing dysphagia, or with neurological conditions that can cause dysphagia (e.g. multiple sclerosis, parkinson's disease, alzheimer's, myasthenia gravis). * patients with chronic kidney disease, defined as a glomerular filtration rate \<60 ml/min. * patients discharged with a terminal condition and/or life expectancy of less than 3 months. * diagnosis of hiv, upon receiving clinical follow-up by the team of specialists.

Keywords: enteral nutrition nutritional assessment nutritional therapy deglutition disorders rehabilitation
acute abdomen in adults- a prospective study on emergency department admissions

Conditions: Abdominal Pain

Summary: this is a non-randomized, prospective, population-based, single-center study designed to evaluate conditions resulting emergency admission in patients with abdominal pain. furthermore, we are interested in how many patients are discharged with "non-specific abdominal pain" but later readmitted and diagnosed with a specific diagnosis.

1000 adult patients with acute abdominal pain will be recruited at tampere university hospital emergency department. the patients will fill in a questionaire about the symptoms and their duration. a urine sample will be collected for polyamine molecule analysis with an electronic nose. at later stage of the study, a serum sample for coeliac tests will be collected. patient outcome will be obtained during the hospital stay, at one-month after discharge and at one year.

Eligibility criteria:
inclusion criteria: all adult patients with abdominal pain. exclusion criteria: under the age of 18 years

Keywords: abdominal pain adult emergency department electronic nose celiac disease
registry of patients with brain tumors treated with start (gammatiles)

Conditions: Brain Tumor, Recurrent; Brain Tumor; Brain Tumor, Primary; Brain Tumor - Metastatic; Brain Tumor, Adult: Glioblastoma; Brain Tumor, Adult Meningioma

Summary: the objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of start.

patients (n=600) with surgically resected (r) brain tumors of any pathology who have undergone start are eligible. data collected will include local control, overall survival, qol, neurocognition, functional decline, and surgical and radiation associated ae's. data will be collected at 1, 3, 6, 9,12, 18 and 24 months, then every 6 months through 5 years. result: data will be used to benchmark clinical outcomes of start therapy and allow for comparisons to existing standard-of-care treatments. this will be the first observational registry study of r+start, delivered by cs-131 sources in permanently implanted resorbable collagen tile carriers. the outcome measures captured will allow for evaluation of the potential risks and benefits of this treatment approach for patients in a real-world setting.

Eligibility criteria:
inclusion criteria: 1. patients who undergo maximum safe resection of intracranial neoplasm(s) and implantation of gammatiles. 2. willing and able to provide informed consent and to participate in all evaluations. exclusion criteria: 1. inability to undergo pre-operative and post-operative imaging for disease and implant assessment. 2. major medical or psychiatric illness, which, in the investigator's opinion would prevent completion of treatment, ability to complete assessments at the time of enrollment, and/or interfere with follow ups. 3. lack of english language fluency sufficient to allow for completion of neurocognitive and qol tests (which are in english).
sparc: shoulder patch for rotator cuff tears

Conditions: Massive Rotator Cuff Tears

Summary: rotator cuff tears (injury to the muscle or tendons which stabilise the shoulder) are one of the most common conditions affecting the shoulder. small and medium sized rotator cuff tears can be managed with arthroscopic or keyhole surgery. very large or massive tears are difficult to operate on and often have poor rates of healing. as a result surgeons have investigated the use of products to improve the outcome of surgery on massive tears. the product that the investigators are currently using to try to improve the outcome of surgery for massive rotator cuff tears is called a patch. the patch provides a scaffold to support the muscles of the rotator cuff. studies of rotator cuff surgery using similar patches have found that recovery is improved and there is a lower rate of postsurgical problems. the aim of this study is to look at whether using the patch improves pain and the clinical function of the shoulder after surgery. in addition, the investigators would like to understand how the patch works. to do this the investigators will scan (take images of) the shoulder using magnetic resonance imaging to look at the muscle damage in the shoulder before and after surgery.


Eligibility criteria:
inclusion criteria: * ultrasound confirming massive rotator full thickness tear, unacceptable pain and disability following conservative treatment, or previous surgery that has failed, deltoid muscle that is functional, and compliance with post operative rehabilitation. exclusion criteria: * history of infection * neurological condition that affects the shoulder girdle * presence of rotator cuff arthropathy with stiffness * subjects with inability to give informed consent * pregnancy or lactation * malignancy * age less than 18 years * subjects currently participating in other research studies * subjects with the following contraindications to mri scanning will not have an mr scan but may be asked to have alternative imaging, for example ultrasound: * pacemakers * surgical clips within the head * certain inner ear implants * neuroelectrical stimulators * metal fragments within the eye or head * pregnant or breastfeeding women
maternal vit d supplements & infant and maternal biomarkers & outcomes in southern ethiopia

Conditions: Vitamin D Deficiency

Summary: synthesis of vitamin d in the skin through the action of sunlight is a major source of vitamin d in parts of the world where foods are not fortified with the vitamin. skin pigmentation (color), dress habits and season are some of the factors that limit sun exposure and affect vitamin d synthesis in the skin. maternal vitamin d status is especially important to meet infant needs when newborns are not supplemented with vitamin d. in ethiopia, vitamin d status of lactating women and infants and breast milk vitamin d concentration have never been assessed. the purpose of this study is to assess changes in maternal and infant markers of vitamin d status before and after vitamin d supplementation of the lactating mothers.

vitamin d is a vitamin that regulates calcium and phosphorous homeostasis and ensures proper mineralization of bone. lactating women and infants are considered to be at risk of vitamin d deficiency due to increased needs for vitamin d and calcium. stores of vitamin d acquired in utero and breast milk are the main sources of vitamin d for infants. maternal vitamin d deficiency, exclusive breastfeeding, skin pigmentation and limited sun exposure are commonly seen in infants with rickets. however, the uv exposure, dress habits, traditional practices and other risk factors to vitamin d deficiency in ethiopia have not been explored. this study aims to fill this research gap.

Eligibility criteria:
inclusion criteria: * breastfeeding * available for enrollment within 2 weeks of delivery * residing in the study area in ethiopia * apparently healthy exclusion criteria: * self-reported chronic or acute disease condition * not breastfeeding * twin births

Keywords: vitamin d supplementation lactation 25 hydroxyvitamin d breast feeding
heart rate variability in white coat hypertension and essential hypertension

Conditions: Essential Hypertension; White Coat Hypertension; Healthy

Summary: the aim of the study is to investigate heart rate variability in patients with white coat hypertension and patients with essential hypertension.


Eligibility criteria:
inclusion criteria: * age 30-70 years * office bp \>150/95 mmhg and 24-h ambulatory bp =/\>135/85 mmhg * office bp \>150/95 mmhg and 24-h ambulatory bp \<135/85 mmhg * office bp \<150/95 mmhg and 24-h ambulatory bp \<135/85 mmhg exclusion criteria: * clinical signs of disease of the heart, lungs, liver, kidneys, brain or endocrine organs * neoplastic disease * daily use of medicine * alcohol abuse * abnormal laboratory screening including blood-hemoglobin, blood-white cell count, plasma-creatinine, plasma-alanine-amino-transaminases, plasma-albumin, plasma-sodium, plasma-potassium, urinary glucose, urinary albumin; electrocardiogram * pregnancy * unwillingness to participate
study of multifunctional cataract-assisted retractor in complicated cataract surgery

Conditions: Subluxation of Lens; Surgical Instruments，Cataract

Summary: to compare the safety and efficacy of a new multi-functional cataract-assisted surgical instrument with that of traditional cataract-assisted surgical instrument in cataract surgery with subluxation of lens.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of lens subluxation. * patients need to undergo lens subluxation surgery exclusion criteria: * active intraocular inflammation * the intraocular pressure (iop) was higher than 25 mmhg * the endothelial cell count (ecc) was less than 1,200 cells/mm2 * combined with other eye diseases * combined with other serious systemic diseases
anonymous survey of breast cancer patients concerning their use of medical apps

Conditions: Health Care Survey

Summary: breast cancer patients complete questionnaires concerning their use of medical apps.

breast cancer patients of the department of gynecology at technical university of munich and berlin charité complete quesionnaires during routine appointments. intention of the survey is to evaluate the importance of medical apps and the special needs of breast cancer patients. moreover approaches to improve health care of breast cancer patients are expected to be developed.

Eligibility criteria:
inclusion criteria: * breast cancer patients * patients who are legally competent and able to understand and follow instructions of the study staff exclusion criteria: * none
safety and effectiveness of daily dosing with 37.5 mg sunitinib malate in patients with advanced kidney cancer

Conditions: Carcinoma, Renal Cell

Summary: a phase ii study to allow patients with advanced kidney cancer access to sunitinib malate treatment and to find out the good and bad effects of taking 37.5 mg sunitinib malate in a continuous daily regimen (once per day) for one year.


Eligibility criteria:
inclusion criteria: * advanced kidney cancer exclusion criteria: * previous treatment for kidney cancer, except surgical removal of kidney tumor
a study of a retroviral replicating vector combined with a prodrug administered to patients with recurrent malignant glioma

Conditions: Glioblastoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma

Summary: this is a multicenter, open-label, ascending-dose trial of the safety and tolerability of increasing doses of toca 511, a retroviral replicating vector (rrv), administered to patients with recurrent high grade glioma (rhgg) who have undergone surgery followed by adjuvant radiation therapy and chemotherapy. patients will receive toca 511 either via stereotactic, transcranial injection into their tumor or as an intravenous injection given daily for 3 \& 5 days, depending on cohort. approximately 3-4 weeks following injection of the rrv, treatment with toca fc, an antifungal agent, will commence and will be repeated approximately every 6 weeks until study completion. after completion of this study, all patients will be eligible for enrollment and encouraged to enter a long-term continuation protocol that enables additional toca fc treatment cycles to be given, as well as permits the collection of long-term safety and survival data.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * for intratumoral cohorts, supratentorial hgg (who grade iii or iv) * technically unresectable hgg * initial definitive therapy such as surgery with or without adjuvant radiation * subject elected not to undergo treatment with gliadel wafer * if receiving corticosteroids, dose is stable or decreasing for past 7 days * kps: at least 70 * absolute neutrophil count \> 1500/mm\^3 * absolute lymphocyte count \> 500/mm\^3 * platelet count \> 100,000/mm\^3 * hemoglobin \> 10 g/dl * for intratumoral cohort, coagulation profile favorable to surgery * estimated glomerular filtration rate \> 50 ml/min * alt \< 3 times uln and bilirubin \< 1.5 mg/dl * negative serum pregnancy test exclusion criteria: * cytotoxic therapy within the past 4 weeks (6 weeks for bcnu/ccnu) * more than 2 recurrences including present recurrence * gliadel wafer or wafers implanted within the past 8 weeks * taking more than 8 mg of dexamethasone per day * for intratumoral cohorts, injection of tumor would require violation of ventricular system * any infection requiring antibiotic, anticoagulant, or antiplatelet agents within the past 4 weeks * for intratumoral cohort, bleeding diathesis or use of anticoagulants/antiplatelet agents that cannot be stopped * allergy or intolerance to 5-fc * hiv positive * g.i. condition that would prevent ingestion or absorption of 5-fc * any investigational treatment within the past 30 days * pregnant or breast feeding * received avastin * history of prior malignancy, excluding basal or squamous cell carcinoma of the skin, with an expected survival of less than 5 years.

Keywords: glioma glioblastoma glioblastoma multiforme grade iv astrocytoma brain cancer recurrent glioblastoma gbm aa aod anaplastic astrocytoma anaplastic oligodendroglioma anaplastic oligoastrocytoma malignant glioma high grade glioma
advantage® prosthetic heart valve long-term follow-up trial

Conditions: Heart Valve Stenosis

Summary: the objective of this study is to assess long term safety and durability of the advantage prosthetic heart valve.

the objective of this study is to assess long term safety and durability of the advantage prosthetic heart valve in patients who were already implanted with this device.

Eligibility criteria:
inclusion criteria: * participated in the advantage prosthetic heart valve study in herz- und diabeteszentrum (bad oeynhausen) or deutsches herzzentrum (munich) * signed and dated patient data release form * available for follow-up exclusion criteria: * high probability of non-adherence to physician's follow-up requirements

Keywords: advantage non-interventional post market release study germany treated with advantage prosthetic heart valve